Form 4: Atara Biotherapeutics Insider Reports Stock Transaction
Insider Transaction (Form 4)
Redmile Group, LLC and 1 other reported changes in beneficial ownership of Atara Biotherapeutics, Inc. common stock on July 22, 2026.
Summary
- Option exercise/conversion: acquired 195,211 Common Stock on July 22, 2026; holds 636,912 after (Indirect).
- Tax/exercise-price withholding: disposed of 60 Common Stock on July 22, 2026; holds 636,852 after (Indirect).
- Option exercise/conversion: disposed of 101,089 Pre-Funded Warrants to Purchase Common Stock on July 22, 2026 (Indirect).
- Option exercise/conversion: disposed of 38,735 Pre-Funded Warrants to Purchase Common Stock on July 22, 2026 (Indirect).
- Option exercise/conversion: disposed of 55,387 Pre-Funded Warrants to Purchase Common Stock on July 22, 2026 (Indirect).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Redmile Group, LLC — Director
Jeremy Green — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-22 | Option exercise/conversion | Common Stock | 195,211 | — | — | 636,912 |
| 2026-07-22 | Tax/exercise-price withholding | Common Stock | 60 | — | — | 636,852 |
| 2026-07-22 | Option exercise/conversion | Pre-Funded Warrants to Purchase Common Stock | 101,089 | — | — | 0 |
| 2026-07-22 | Option exercise/conversion | Pre-Funded Warrants to Purchase Common Stock | 38,735 | — | — | 0 |
| 2026-07-22 | Option exercise/conversion | Pre-Funded Warrants to Purchase Common Stock | 55,387 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-22 | Option exercise/conversion (195,211 shares) |
| 2026-07-22 | Tax/exercise-price withholding (60 shares) |
| 2026-07-22 | Option exercise/conversion (101,089 shares) |
| 2026-07-22 | Option exercise/conversion (38,735 shares) |
| 2026-07-22 | Option exercise/conversion (55,387 shares) |
Keywords
insider transaction, Form 4, ATRA, Atara Biotherapeutics, Inc., neutral, Redmile Group, LLC, Jeremy Green
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.